Lifecore Biomedical (LFCR) said Tuesday it has signed a new 10-year commercial manufacturing and supply agreement with an existing customer.
Financial terms weren't disclosed, and Lifecore didn't identify the customer.
The company said the deal is the latest between the two firms to support the advancement of a new ophthalmic therapy from clinical development to the market.
In conjunction with the agreement, Lifecore said it has also signed a multi-million-dollar statement of work detailing a range of fill-and-finish services that include manufacturing batches of the drug candidate.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。